Perspectives on novel therapies for bronchial carcinoma

Expert Opin Pharmacother. 2005 Jun;6(7):1157-67. doi: 10.1517/14656566.6.7.1157.

Abstract

Improvements in conventional cytotoxic treatment have probably reached a plateau for the treatment of lung cancer; therefore, new treatment strategies that are based on a better understanding of tumour biology are required. Some progress has been made for non-small cell lung cancer, in which erlotinib (Tarceva, OSI-774; Genentech), an epidermal growth factor receptor antagonist, has demonstrated a significant clinical benefit in a Phase III randomised trial, and has been licensed for second- or third-line treatment. Other therapies under investigation include angiogenesis inhibitors, COX-2 inhibitors, retinoids, farnesyl transferase inhibitors, Bcl-2 inhibitors and c-Kit antagonists. In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab
  • Carcinoma, Bronchogenic / drug therapy*
  • Carcinoma, Bronchogenic / enzymology
  • Carcinoma, Small Cell / drug therapy*
  • Carcinoma, Small Cell / enzymology
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Drug Administration Schedule
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Patient Selection
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / therapeutic use
  • Quinazolines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sulfonamides / therapeutic use
  • Vascular Endothelial Growth Factor A / immunology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Cyclooxygenase 2 Inhibitors
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Quinazolines
  • Sulfonamides
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Celecoxib